60 Degrees Pharmaceuticals, Inc. (SXTP), Tuesday announced the potential maximum size of the commercial market for ARAKODA, projecting it to be 380,000 patients/$245,000,000 in sales annually, with a cumulative total addressable market of 1.17 million patients/$1.1 billion through patent expiration in 2035.
Notably, the total addressable market for ARAKODA for treatment of babesiosis, a serious and debilitating emerging tick-borne illness, was based on data from a 6,000 nationwide patient survey and a quantitative research study involving 300 healthcare professionals.
The company added that it intends to file for New Drug Application in 2026.
In the pre-market hours, SXTP is trading at $2.55, up 17.78 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.